跳转至内容
Merck
CN
所有图片(1)

主要文件

安全信息

SML0650

Sigma-Aldrich

Risedronate sodium

≥97% (HPLC)

别名:

P,P′-[1-Hydroxy-2-(3-pyridinyl)ethylidene]bis-phosphonic acid sodium, Sodium risedronate, [1-Hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic acid] monosodium salt

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C7H10NO7P2 · Na
分子量:
305.09
UNSPSC代码:
41106300
NACRES:
NA.77

质量水平

方案

≥97% (HPLC)

表单

powder

颜色

white to beige

溶解性

H2O: 5 mg/mL, clear (warmed)

储存温度

room temp

SMILES字符串

[Na+].[P](=O)([O-])(O)[C@]([P](=O)(O)O)(O)Cc1cnccc1

InChI

1S/C7H11NO7P2.Na/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6;/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15);/q;+1/p-1

InChI key

DRFDPXKCEWYIAW-UHFFFAOYSA-M

生化/生理作用

Risedronate sodium is a bisphosphonate bone resorption inhibitor. It has an affinity for hydroxyapatite crystals in bone and acts as an antiresorptive agent and is an inhibitor of farnesyl diphosphate (FPP) synthase, which results in downstream inhibition of osteoclast activity and reduced bone resorption and turnover. Risedronate sodium has been used to treat postmenopausal osteoporosis and Paget′s disease.

象形图

Exclamation mark

警示用语:

Warning

危险声明

危险分类

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Amy L Inselman et al.
Frontiers in pharmacology, 15, 1365151-1365151 (2024-05-01)
Preparations of black cohosh extract are sold as dietary supplements marketed to relieve the vasomotor symptoms of menopause, and some studies suggest it may protect against postmenopausal bone loss. Postmenopausal women are also frequently prescribed bisphosphonates, such as risedronate, to
Seiji Ohtori et al.
Spine, 38(8), E487-E492 (2013-01-29)
Prospective study. To examine the efficacy of teriparatide or bisphosphonate treatment to reduce pedicle screw (PS) loosening after instrumented lumbar posterolateral fusion in postmenopausal women with osteoporosis. Failure of fixation caused by loosening of PSs in osteoporosis is a problem
J B Matheny et al.
Bone, 57(1), 277-283 (2013-08-31)
Alterations in resorption cavities and bone remodeling events during anti-resorptive treatment are believed to contribute to reductions in fracture risk. Here, we examine changes in the size of individual remodeling events associated with treatment with a selective estrogen receptor modulator
Irit Ben-Aharon et al.
PloS one, 8(8), e70044-e70044 (2013-08-31)
The role of bisphosphonates (BP) in early breast cancer (BC) has been considered controversial. We performed a meta-analysis of all randomized controlled trials (RCTs) that appraised the effects of BP on survival in early BC. RCTs were identified by searching
Job F M van Boven et al.
Journal of bone and mineral metabolism, 31(5), 562-570 (2013-04-12)
Low persistence with osteoporosis medication is associated with higher fracture risk. Previous studies estimated that 1-year persistence with osteoporosis medication is low. Our aim was to study persistence with osteoporosis medication among patients with long-term follow-up (to 5 years). The InterAction

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门